Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin in elderly diabetic patients with MCI
NCT03819127Phase 4Completed
- Sponsor
- University of Catania
- Start
- Jan 2015
- Primary completion
- Sep 2016
- Modality
- Small Molecules
01
Overview
Phase 4, open-label trial of vildagliptin in Mild Cognitive Impairment (MCI) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by University of Catania. Primary endpoint: Evaluation of cognitive decline at 24 weeks. Started Jan 2015; status: completed.
02
Drugs
vildagliptin
03
Conditions
Mild Cognitive Impairment (MCI)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03819127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03819127.